Save the date: Alligator Bioscience to host Capital Markets Day in Stockholm on 29 May 2018

Lund, Sweden, 18 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will host a Capital Markets Day in Stockholm on Tuesday 29 May 2018 for investors, analysts and media.

The event will provide a detailed update on Alligator’s project pipeline, including a discussion on the future development of immuno-oncology antibodies.

The program will start at 2:00 pm CEST, with registration from 1:00 pm CEST and will end with networking at 5:00 pm CEST. The event will take place at GT30, room Turbinen, Grev Turegatan 30 in Stockholm.

The event will be conducted in English and there will be a simultaneous live conference call and webcast for those unable to attend in person. The webcast, with presentation slides, will be available to view on Alligator’s website www.alligatorbioscience.com and a recording will be made available shortly after the event.

If you wish to register for the event, please send an email to anmalan@alligatorbioscience.com with the subject “CMD 29 May”.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
E-mail: cecilia.hofvander@alligatorbioscience.com 

The information was submitted for publication, through the agency of the contact person set out above, at 2:30 p.m. CEST on 18 April 2018.

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.

About Us

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees.